文献速递血栓与止血

利伐沙班在儿童脑静脉血栓中的安全性与有效性

Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT).
PubMed 文献 · Blood Adv · 2020-01-01

儿童脑静脉血栓的抗凝治疗缺乏随机试验证据。EINSTEIN-Jr试验预设亚组纳入114例确诊CVT患儿,初始肝素化后按2:1随机接受利伐沙班或标准抗凝治疗3个月。两组症状性复发性VTE和临床相关出血风险均较低,利伐沙班组无复发性VTE,标准抗凝组1例;出血事件分别为5例和1例,均为探索性分析。

要点

  • 利伐沙班治疗儿童CVT的复发性VTE风险低,3个月内无事件。
  • 临床相关出血以非重大非脑出血为主,标准抗凝组见1例硬膜下重大出血。

核心结论

  • 在样本量有限的随机试验亚组中,利伐沙班或标准抗凝治疗儿童CVT的复发性VTE和临床相关出血风险均较低。

研究设计与样本

  • EINSTEIN-Jr试验预设亚组,纳入114例确诊CVT患儿,初始肝素化后按2:1随机分配至利伐沙班或标准抗凝治疗,主要治疗期3个月。

主要发现

  • 利伐沙班组73例中0例发生症状性复发性VTE,标准抗凝组41例中1例(2.4%)发生,绝对差异2.4%(95%CI -2.6%至13.5%)。
  • 临床相关出血在利伐沙班组5例(6.8%,均为非重大非脑出血),标准抗凝组1例(2.5%,硬膜下重大出血),绝对差异4.4%(95%CI -6.7%至13.4%)。
  • 完全或部分窦再通在利伐沙班组分别为18例(25%)和39例(53%),标准抗凝组分别为6例(15%)和24例(59%)。

关键数值与推荐

  • 主要疗效结局为症状性复发性VTE,主要安全结局为重大或临床相关非重大出血,均由盲法研究者中心评估。
  • 窦再通通过重复脑影像评估为次要结局。

临床怎么用

  • 对于儿童CVT,利伐沙班可作为标准抗凝之外的潜在选择,但需注意样本量有限且分析为探索性。

局限性

  • 亚组样本量有限,统计分析为探索性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anticoagulant treatment of pediatric cerebral venous thrombosis has not been evaluated in randomized trials. We evaluated the safety and efficacy of rivaroxaban and standard anticoagulants in the predefined subgroup of children with cerebral venous thrombosis (CVT) who participated in the EINSTEIN-Jr trial. Children with CVT were randomized (2:1), after initial heparinization, to treatment with rivaroxaban or standard anticoagulants (continued on heparin or switched to vitamin K antagonist). The main treatment period was 3 months. The primary efficacy outcome, symptomatic recurrent venous thromboembolism (VTE), and principal safety outcome, major or clinically relevant nonmajor bleeding,were centrally evaluated by blinded investigators. Sinus recanalization on repeat brain imaging was a secondary outcome. Statistical analyses were exploratory. In total, 114 children with confirmed CVT were randomized. All children completed the follow-up. None of the 73 rivaroxaban recipients and 1 (2.4%; CVT) of the 41 standard anticoagulant recipients had symptomatic, recurrent VTE after 3 months (absolute difference, 2.4%; 95% confidence interval [CI], -2.6% to 13.5%). Clinically relevant bleeding occurred in 5 (6.8%; all nonmajor and noncerebral) rivaroxaban recipients and in 1 (2.5%; major [subdural] bleeding) standard anticoagulant recipient (absolute difference, 4.4%; 95% CI, -6.7% to 13.4%). Complete or partial sinus recanalization occurred in 18 (25%) and 39 (53%) rivaroxaban recipients and in 6 (15%) and 24 (59%) standard anticoagulant recipients, respectively. In summary, in this substudy of a randomized trial with a limited sample size, children with CVT treated with rivaroxaban or standard anticoagulation had a low risk of recurrent VTE and clinically relevant bleeding. This trial was registered at clinicaltrials.gov as #NCT02234843.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Connor P, Sánchez van Kammen M, Lensing AWA, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020. PMID: 33351120. doi:10.1182/bloodadvances.2020003244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。